Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 2

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NCT03808662 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse

Interventions

  • DRUG Standard of care
  • RADIATION Sterotactic Body Radiotherapy/SBRT

Study Locations (10)

New York

  • Memorial Sloan Kettering Commack — Commack
  • Memorial Sloan Kettering Westchester — Harrison
  • Memorial Sloan Kettering Cancer Center — New York
  • Memorial Sloan Kettering Rockville Centre — Rockville Centre
  • Memorial Sloan Kettering Nassau — Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge — Basking Ridge
  • Memorial Sloan Kettering Monmouth — Middletown
  • Memorial Sloan Kettering Bergen — Montvale

Washington

  • Fred Hutchinson Cancer Research Center (Data Analysis Only) — Seattle

Ontario

  • Princess Margaret Hospital/Ontario Cancer Institute (Data Analysis Only) — Toronto

Trial Details

FieldValue
Enrollment Target 107 participants
Start Date 2019-01-16
Est. Completion 2027-01
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

2,280 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03808662

The ClinicalTrials.gov registry entry for NCT03808662 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 2,280 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 7 conditions, with Non Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions — of which Standard of care is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03808662 reports 10 study locations spanning 4 distinct geographic areas — top geographies include New York, New Jersey, Washington. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03808662 about?

NCT03808662 is a clinical study titled "Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung". The purpose of this study is determine if receiving stereotactic body radiation(SBRT) when participants' metastatic tumors have just begun to grow increase the length of time before disease gets worse

What is the current status of trial NCT03808662?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 107 participants. The study started on 2019-01-16. Estimated completion is 2027-01.

What conditions does trial NCT03808662 study?

This clinical trial studies the following conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, NSCLC, TNBC - Triple-Negative Breast Cancer, Non Small Cell Lung Cancer Metastatic. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03808662?

The interventions under investigation include: Standard of care (DRUG), Sterotactic Body Radiotherapy/SBRT (RADIATION). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03808662?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 2,280 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03808662 being conducted?

This trial has 10 study locations across New Jersey, New York, Washington, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial